Subscribe to our Newsletters !!
Cell therapy is a medical breakthrough in addressi
Chromium, a transition metal with profound pharmac
Few names in the medical history have had a profou
We are pleased to announce that we have recently e
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of Mi
Sanofi And GSK said they had reached a deal with Britain to provide it with as much as 60 million doses of an expected COVID-19 vaccine, and that discussions with different authorities were ongoing.
No Vaccine has been prescribed to treat or protect against COVID-19, the respiratory disorder caused by the new coronavirus which has killed over 659,000 people and triggered economic havoc globally.
Financial Details of the arrangement weren’t disclosed. Sanofi and GSK, that had first teamed up in April, confirmed in a statement that regulatory approval for their vaccine might be reached by the initial half 2021 if clinical data was to be positive.
The Initial clinical trials are anticipated in September.
The Vaccine will be developed by blending Sanofi’s S-protein COVID-19 antigen along with GSK’s pandemic adjuvant technology.
Adjuvants Are efficiency boosters which play a very important role in several vaccines. An adjuvant is added to your vaccines to improve the immune reaction, and has been shown to make a more powerful and longer lasting immunity against diseases than a vaccine alone.
Sanofi And GSK said other talks with the European Union, Italy and France to provide their vaccine were continuing.
Sanofi The company wanted to secure an upfront payment for the entire inventory while the EU would rather postpone payments before the vaccine has passed substantial clinical trials.
